endpts.com endpts.com

ENDPTS.COM

ENDPOINTS NEWS – Biotech business news and analysis

Thursday, January 12, 2017. IBB 277.94 8.56 (2.99%). XBI 63.49 2.26 (3.44%). CNCR 22.32 0.52 (2.28%). Free newsletter, 2x daily. Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals. Donald Trump promises to slash drug prices by billions, pledging aggressive federal bidding process. In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer. FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues. Amgen, Sanofi and M...

http://www.endpts.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR ENDPTS.COM

TODAY'S RATING

#193,968

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.0 out of 5 with 5 reviews
5 star
0
4 star
5
3 star
0
2 star
0
1 star
0

Hey there! Start your review of endpts.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.7 seconds

FAVICON PREVIEW

  • endpts.com

    16x16

  • endpts.com

    32x32

  • endpts.com

    64x64

  • endpts.com

    128x128

  • endpts.com

    160x160

  • endpts.com

    192x192

  • endpts.com

    256x256

CONTACTS AT ENDPTS.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
ENDPOINTS NEWS – Biotech business news and analysis | endpts.com Reviews
<META>
DESCRIPTION
Thursday, January 12, 2017. IBB 277.94 8.56 (2.99%). XBI 63.49 2.26 (3.44%). CNCR 22.32 0.52 (2.28%). Free newsletter, 2x daily. Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals. Donald Trump promises to slash drug prices by billions, pledging aggressive federal bidding process. In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer. FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues. Amgen, Sanofi and M...
<META>
KEYWORDS
1 endpoints news logo
2 ticker
3 current price
4 change
5 graph
6 cncr
7 last updated
8 menu
9 chat
10 special reports
CONTENT
Page content here
KEYWORDS ON
PAGE
endpoints news logo,ticker,current price,change,graph,cncr,last updated,menu,chat,special reports,deep dives,marco,news,protocols,bioregnum,thumbs up/down,people ipos,vision or voodoo,politics pricing,immuno oncology,latest,rarr;,top news,secretive,a day
SERVER
nginx
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

ENDPOINTS NEWS – Biotech business news and analysis | endpts.com Reviews

https://endpts.com

Thursday, January 12, 2017. IBB 277.94 8.56 (2.99%). XBI 63.49 2.26 (3.44%). CNCR 22.32 0.52 (2.28%). Free newsletter, 2x daily. Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals. Donald Trump promises to slash drug prices by billions, pledging aggressive federal bidding process. In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer. FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues. Amgen, Sanofi and M...

INTERNAL PAGES

endpts.com endpts.com
1

CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns – ENDPOINTS NEWS

https://endpts.com/curevacs-lead-mrna-program-flunks-a-critical-phiib-study-raising-questions-for-high-profile-biotech-unicorns

Thursday, March 9, 2017. IBB 297.65 2.62 (0.89%). XBI 70.61 1.02 (1.47%). CNCR 23.76 0.24 (1.02%). Free newsletter, 2x daily. CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns. January 12, 2017 04:40 AM EST. Share a link to this article. CureVac’s leading mRNA program CV9104, a prostate cancer vaccine, has failed. The most prominent company in the messenger RNA space is Moderna, a Boston-based biotech which has raised $1.9 billion and just ...

2

Protocols – ENDPOINTS NEWS

https://endpts.com/protocols

Thursday, March 9, 2017. IBB 297.65 2.62 (0.89%). XBI 70.61 1.02 (1.47%). CNCR 23.76 0.24 (1.02%). Free newsletter, 2x daily. Soon-Shiong blasts back at maliciously false STAT story; ImmunoMet raises $5M. March 8, 2017 10:09 AM EST. Soon-Shiong’s NantHealth tanks on STAT report of self-dealing; Bioversys, Aptuit forge antibiotic collab; Helix gets new CEO. March 7, 2017 09:28 AM EST. GSK vet named CEO of China CAR-T JV with Kite; Coherus fights back against Amgen claims it stole trade secrets. You can al...

3

An introduction to the Endpoints 100 – ENDPOINTS NEWS

https://endpts.com/an-introduction-to-the-endpoints-100

Thursday, March 9, 2017. IBB 297.65 2.62 (0.89%). XBI 70.61 1.02 (1.47%). CNCR 23.76 0.24 (1.02%). Free newsletter, 2x daily. An introduction to the Endpoints 100. August 10, 2016 11:37 AM EST. October 18, 2016 06:20 AM. Share a link to this article. John Carroll, Editor. I’m well into a new project at. That I’d like to tell you about. It’s called the. Update: List of executives is at the bottom of this article.). As my partner Arsalan Arif and I craft this niche biotech news company over the coming year...

4

Thumbs Up/Down – ENDPOINTS NEWS

https://endpts.com/thumbs-updown

Thursday, March 9, 2017. IBB 297.65 2.62 (0.89%). XBI 70.61 1.02 (1.47%). CNCR 23.76 0.24 (1.02%). Free newsletter, 2x daily. There has to be a better way to handle Duchenne drugs; Let’s get to the bottom of the Juno debacle. March 3, 2017 09:33 AM EST. March 6, 2017 07:54 AM. Let’s not forget why biopharma megamergers are such an awful idea. February 24, 2017 08:55 AM EST. Another price-gouging CEO proves the system is broken, underscoring need for principled reform at the FDA. February 13, 2017 08:16 AM.

5

FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues – ENDPOINTS NEWS

https://endpts.com/tesaros-shares-dented-by-fda-rejection-of-rolapitant-iv

Thursday, March 9, 2017. IBB 297.65 2.62 (0.89%). XBI 70.61 1.02 (1.47%). CNCR 23.76 0.24 (1.02%). Free newsletter, 2x daily. FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues. January 12, 2017 05:39 AM EST. Share a link to this article. Mary Lynne Hedley, Tesaro President and COO. Regulators did not question the safety and efficacy of the IV version, Tesaro reported, but did have issues with the biotech’s switch of manufacturers. After identifying potential deficiencies at t...

UPGRADE TO PREMIUM TO VIEW 15 MORE

TOTAL PAGES IN THIS WEBSITE

20

SOCIAL ENGAGEMENT



OTHER SITES

endpsalzinnes.be endpsalzinnes.be

Ecole Notre-Dame Primaire - Salzinnes

Présentation, projet d’établissement,. Règlement d’ordre intérieur,. Restauration, bibliothèque,. Équipe et organisation des classes. Classes de découvertes,.

endpsk.com endpsk.com

Apache HTTP Server Test Page powered by CentOS

Apache 2 Test Page. This page is used to test the proper operation of the Apache HTTP server after it has been installed. If you can read this page it means that the Apache HTTP server installed at this site is working properly. If you are a member of the general public:. The fact that you are seeing this page indicates that the website you just visited is either experiencing problems or is undergoing routine maintenance. If you are the website administrator:. You may now add content to the directory.

endpsoriasis.com endpsoriasis.com

How I End Psoriasis

THIS IS……… PANDORA HO. LIVE HAPPILY WITH PSORIASIS, PATCH-FREE -. My name is Pandora HO. I’m 46 years old and living in Hong Kong. I started to have red scaly patches when I was 13/14 years old. My Psoriasis condition has been relieved since I started using Dr. Chen's potion and cream. I tried not to use anything containing Steroids. I never paid attention to the "skin thinning" problem, until it appeared over my underarm and my inner thighs. Every morning after showering, I will put. Since 1999 I have b...

endpt.com endpt.com

Endpoint Security - Home

endpt.ibbl.ws endpt.ibbl.ws

«« ENDESA GENERACION PORTUGAL »»

Pedimos desculpa pelo incómodo, mas procedemos neste momento a uma manutenção do site. Por favor volte a tentar mais tarde.

endpts.com endpts.com

ENDPOINTS NEWS – Biotech business news and analysis

Thursday, January 12, 2017. IBB 277.94 8.56 (2.99%). XBI 63.49 2.26 (3.44%). CNCR 22.32 0.52 (2.28%). Free newsletter, 2x daily. Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals. Donald Trump promises to slash drug prices by billions, pledging aggressive federal bidding process. In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer. FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues. Amgen, Sanofi and M...

endptsd.com endptsd.com

Price Request - BuyDomains

Url=' escape(document.location.href) , 'Chat367233609785093432', 'toolbar=0,scrollbars=0,location=0,statusbar=0,menubar=0,resizable=0,width=640,height=500');return false;". Need a price instantly? Just give us a call. Toll Free in the U.S. We can give you the price over the phone, help you with the purchase process, and answer any questions. Get a price in less than 24 hours. Fill out the form below. One of our domain experts will have a price to you within 24 business hours. United States of America.

endptsd.org endptsd.org

Web Page Under Construction

This Site Is Under Construction and Coming Soon. This Domain Is Registered with NameSecure.

endpubliceducation.com endpubliceducation.com

My Site

This is my site description. A website created by GoDaddy’s Website Builder.

endpublishing.com endpublishing.com

www.endpublishing.com

This Web page parked FREE courtesy of Cheap-Domain Registration.com. Search for domains similar to. Is this your domain? Let's turn it into a website! Would you like to buy this. Find Your Own Domain Name. See our full line of products. Easily Build Your Professional Website. As low as $4.99/mo. Call us any time day or night (480) 624-2500.

endpulse.com endpulse.com

Endpulse Software - Welcome

Welcome to Endpulse Software. Endpulse Software helps webmasters by providing them with tools for improving their websites. Currently we offer you Joomla! Trace the most useful tool you may ever need for studying your visitors' / customers' behavior. Is Free Software released under the GNU/GPL License.